Monitor the next quarterly earnings release for any changes in financial strategy or capital allocation under the new CFO. The transition appears orderly and non-disruptive.
Drugs in focus
SNDX drug pipeline →Niktimvo
▲ Bullish Named in this press release- Impact
- Phase
- Approved
- Time to market
- Already approved and commercially launched (FDA approved August 2024)
- Next catalyst
- None dated
What to watchNiktimvo's commercial trajectory is the primary value driver for SNDX on this drug. Watch Q2/Q3 2026 net revenue prints for signs of continued ramp ($151.6M FY2025 annualizing to ~$220M in Q1 2026). The Phase 2 IPF readout in Q4 2026 is an important optionality catalyst that could open a much larger market, but comes with clinical risk. The $250M convertible note issued June 2026 introduces modest dilution overhang (~8-10% of shares outstanding).
Price Chart
Executive Summary
Syndax Pharmaceuticals announced the appointment of Aaron A. Ondrey as CFO, effective November 9, 2026, replacing Keith A. Goldan who is retiring. The filing is a routine executive transition with no financial results or guidance provided, and no material impact on operations is expected.
Key Facts
- Aaron A. Ondrey appointed as CFO effective November 9, 2026
- Current CFO Keith A. Goldan retiring, will remain through end of 2026 to support transition
- Mr. Ondrey previously CFO at Beren Therapeutics, Rocket Pharmaceuticals, and Mirati Therapeutics
- No financial results, guidance, or operational updates were provided in this press release
Financial Impact
No financial figures disclosed; routine executive change with no stated financial impact.
Risk Factors
- No financial data or guidance provided; the filing is purely a personnel announcement
- CFO transition could introduce temporary uncertainty, though the outgoing CFO is staying through year-end
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3393696 |
Track record
16 reports on SNDX
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 12, 20264d ago 3 Neutral 1/10 Entry $9.45 Now $9.13 −3.39% settles Feb 11
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $9.49 Now $9.13 −3.79% settles Feb 8
- Nov 9, 20267d ago Press Release Neutral 2/10 Entry $9.49 Now $9.13 −3.79% settles Feb 8
- Nov 2, 202614d ago 8-K Neutral 5/10 No price data
- Nov 2, 202614d ago Press Release Neutral 2/10 Viewing No price data
- Nov 2, 202614d ago Press Release Neutral 5/10 Entry $14.29 Now $9.13 −36.11% settles Feb 1
- Oct 29, 202618d ago 144 Neutral 2/10 Entry $13.65 Now $9.13 −33.11% settles Jan 28
- Jul 14, 202617w ago 8-K Bullish 7/10 Entry $24.13 to $17.03 Now $9.13 −62.16% ▼ −29.42% −32.80% vs SPY
- Jul 1, 202619w ago Press Release Neutral 2/10 Entry $21.82 to $18.20 Now $9.13 −58.16% ▼ −16.59% −20.16% vs SPY
- Jun 11, 202622w ago Press Release Bullish 7/10 Entry $17.91 to $20.56 Now $9.13 −49.02% ▲ +14.80% +10.40% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers